December 19, 2012
When our new partner Vetoquinol BIOWET recently launched
Uniferon in Poland, it was celebrated in style.
The renowned Polish company invited their sales personal to a
very inspiring sales meeting/launch event. And they went to great
lengths to kick things off in a proper manner.
Among other things the sales team received a copy of "The
Swineherd" by Danish author Hans Christian Andersen, Danish
delicacies were served at the dinner event, and the whole event
included several national Danish trademarks to set the scene.
International Sales Manager Christian von der Recke attended the
sales meeting and states: "At Pharmacosmos, we sincerely applaud
the creativity shown, and we thank Vetoquinol BIOWET for the great
idea and the warm welcome onto the very promising Polish market for
injectable quality iron."
On this note, we want to thank you all for an exciting 2012,
where Uniferon was launched not only in Poland, but also in France,
Russia, Portugal and in the Baltic countries as well as becoming
available in all Scandinavian countries.
We are delighted to continuously pursue best practice iron
management together with winning pig farmers everywhere, and we
feel confident that 2013 will be equally exciting.
We wish you all a Merry Christmas and a happy New Year.
About Uniferon
Uniferon is a modern improved iron hydrogenated dextran based on
a natural formula, which is approved for global use:
Uniferon is manufactured without the use of any organic solvents
or cyanide, thus, avoiding trace residues of these impurities.
Pharmacosmos manufactures iron dextran of high quality and unique
purity for customers worldwide. Uniferon is the only injectable
iron brand for piglets approved in the EU, the US and Asia.
About Pharmacosmos
Headquartered in Denmark, Pharmacosmos is a family-owned,
international healthcare company with more than 50 years of
innovation and leadership in iron- and carbohydrate-based
treatments and solutions for human and animal use.
A research-based company, its ongoing R&D programme focuses
on improving the lives of patients with iron deficiency with or
without anaemia. More than 1 billion people live with iron
deficiency anaemia and it is the leading cause of death for an
estimated 180,000 people every year. This makes it one of the
largest global health challenges of our time.
Pharmacosmos has subsidiaries in the Nordics, the UK and the US
and its products are marketed in more than 80 countries across the
world. Its manufacturing facilities are approved, among others, by
the Danish Medicines Agency and the US FDA.